ROIV - Roivant Sciences Ltd.
NASDAQ
->
Healthcare
->
Biotechnology
London,
United Kingdom
Type: Equity
ROIV price evolution
ROIV
| (in millions $) | 31 Jan 2025 | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $22.68 | $104.83 | $82.81 | |
| Inventory | $34 | $35.25 | ||
| Total current assets | $5801.12 | $6001.5 | $6731.83 | |
| Long term investments | ||||
| Property, plant & equipment | $56.65 | $63.15 | $65.95 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $6206.03 | $6496.45 | $7222.48 | |
| Current liabilities | ||||
| Accounts payable | $25.13 | $27.74 | $53.23 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $556.25 | $215.04 | $266.76 | |
| Long term debt | $311.72 | $430.59 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1053.07 | $1061.14 | $1253.9 | |
| Shareholders' equity | ||||
| Retained earnings | $395.58 | $671.47 | $576.17 | |
| Other shareholder equity | -$18.04 | -$17.95 | -$4.08 | |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2025 | 1 May 2024 | 1 May 2023 | 1 May 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $82.81 | $32.73 | ||
| Inventory | $35.25 | $2.76 | ||
| Total current assets | $6731.83 | $1798.59 | $2146.52 | |
| Long term investments | ||||
| Property, plant & equipment | $65.95 | $92.34 | $86.95 | |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $7222.48 | $2389.6 | $2585.13 | |
| Current liabilities | ||||
| Accounts payable | $53.23 | $37.83 | $34.58 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $266.76 | $272.45 | $184.37 | |
| Long term debt | $430.59 | $379.09 | $210.02 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $1253.9 | $1231.84 | $523.7 | |
| Shareholders' equity | ||||
| Retained earnings | $576.17 | -$3772.75 | -$2763.72 | |
| Other shareholder equity | -$4.08 | -$2.62 | $403.54 | |
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $4.47 | $7.99 | $28.93 | $37.14 |
| Cost of revenue | ||||
| Gross Profit | $4.24 | $7.78 | $24.52 | $33.47 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $345.95 | $220.4 | $290.52 | $321 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $12.46 | $11.96 | -$8.96 | $25.67 |
| Interest expense | $118.15 | $87.35 | $92.19 | $12.04 |
| Net income | ||||
| Net income | -$230.18 | $95.3 | -$151.12 | $5096.18 |
| Income (for common shares) | ||||
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $124.8 | $61.28 | $55.29 | $23.8 |
| Cost of revenue | ||||
| Gross Profit | $109.23 | $48.15 | -$413.82 | $21.74 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $1189.18 | $1223.47 | $432.07 | $1092.63 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $22.22 | $5.19 | $0.37 | $1.69 |
| Interest expense | $63.67 | -$16.6 | $7.04 | $90.39 |
| Net income | ||||
| Net income | $4348.93 | -$1009.03 | -$845.26 | -$809.23 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$3294.56 | -$0.96 | $5203.62 | $5196.69 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | -$769.69 | -$660.62 | $419.36 | $451.99 |
| Effect of exchange rate | $2.3 | -$2.74 | $0.62 | $1.47 |
| Change in cash and equivalents | -$4521.58 | -$857.15 | $4858.33 | $4993.34 |
| (in millions $) | 1 May 2024 | 1 May 2023 | 1 May 2022 | 1 May 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $5203.62 | -$44.3 | $303.3 | -$31.7 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $419.36 | $499.5 | $306.79 | $456.26 |
| Effect of exchange rate | $0.62 | $6.3 | ||
| Change in cash and equivalents | $4858.33 | -$381.9 | -$67.64 | -$127.58 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | N/A |
| Revenue | $78.53M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | $4.81B |
| Revenue Q/Q | -64.29% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | N/A |
| Quick ratio | N/A |